Samsung Biologics inks $242 mil. CMO deal with BMS
Samsung Biologics signed a $242 million contract manufacturing organization (CMO) deal with global pharmaceutical giant Bristol-Myers Squibb for the production of immuno-oncology drugs, the drug manufacturer said Monday. Samsung said the production agreement was made with BMS' subsidiary Swords Laboratories. Under the contract, its Plant 4 will serve as the production base for BMS' flagship immuno-oncology product for the next seven years through 2030.
Source: koreatimes.co.kr